Antenatal Glucocorticoid Treatment: Are We Doing Harm to Term Babies?
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Antenatal glucocorticoids are given to 7–10% of women in Europe and North America at threat of preterm labor. It is undisputed that this therapy significantly reduces neonatal morbidity and mortality in infants born before 34 wk gestation (1, 2). Based on outcomes from multiple clinical trials, current obstetric practice is to administer either a single 2-d course of betamethasone or dexamethasone (i.e. two 12-mg doses of betamethasone im at 24-h intervals or four 6-mg doses of dexamethasone im at 12-h intervals) to women in preterm labor between 24 and 34 wk gestation (3). The use of repeat courses of antenatal glucocorticoids is more controversial, although some evidence suggests that a repeat course, if the mother does not deliver but remains at risk of preterm labor, may yield neonatal benefit (2). However, because early clinical diagnosis of preterm labor is difficult and there are no reliable laboratory tests, there are a substantial number of women who receive antenatal glucocorticoid treatment yet subsequently deliver babies at full term, i.e. after 37 wk gestation. Little is known about the potential risks or benefits of synthetic glucocorticoid exposure to these infants. It is now well recognized that exposure to an adverse in utero environment during development has long-term effects on physiology and later risk of adult disease (4). Overexposure of the developing fetus to excess glucocorticoids is a key mechanism thought to underlie such “developmental programming” (4). Numerous preclinical studies have shown that administration of dexamethasone to pregnant mothers leads to long-term changes in the offspring, notably permanently altering cardiometabolic and neuropsychiatric functions as well as hypothalamic-pituitary-adrenal (HPA) axis activity (4). The latter may contribute to some of the broader pathogenesis associated with experimental programming. Both betamethasone and dexamethasone have high affinity for glucocorticoid receptors but are poor substrates for the placental enzyme 11-β hydroxysteroid dehydrogenase type 2, which normally acts as a partial barrier, protecting the fetus from glucocorticoids by breaking down endogenous cortisol into inactive cortisone (4). These synthetic glucocorticoids readily cross the placenta, potentially exposing the fetus to excess glucocorticoids. In animal models, the developing HPA axis appears particularly vulnerable to excess glucocorticoids (4), yet the evidence for detrimental effects of antenatal glucocorticoids on human HPA axis activity has been less clear-cut. This is partly because most studies have included preterm infants, who often have coexisting medical complications and are exposed to stressors and painful procedures while in the neonatal intensive care unit, factors that can per se alter HPA axis function (5). Likewise, the type, dose, and timing of administration of glucocorticoid therapy often differ between studies, complicating interpretation. Furthermore, studies have included limited assessments of the offspring HPA axis, often with a single measurement of cortisol levels. Given these caveats, the limited existing data, which include preterm babies in whom the HPA axis may be immature, suggest that among infants exposed to antenatal glucocorticoids, baseline cortisol levels are suppressed during the first postnatal week, and cortisol responses to the painful stress of the heel-stick procedure are suppressed for up to 8 wk (6), suggesting some persistent suppressive effects on HPA axis regulation, but hardly the programming of increased (or reduced) HPA activity seen throughout the lifespan in animal models. In the article by Alexander et al. (7) in this issue of the JCEM, the authors report on the first study to examine the impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children aged 6–10 yr. Maternal stress has itself been implicated as a programming factor (4), and hospitalized women receiving antenatal glucocorticoids are likely to be more worried and “stressed.” Alexander et al. (7) therefore introduced an additional control group of stressed mothers who had been admitted to hospital with pregnancy complications but had not received antenatal glucocorticoids. This careful study design goes some way to disentangle the potential confounding effect of maternal stress from the direct effects of antenatal glucocorticoid exposure. The children exposed to antenatal glucocorticoids were smaller at birth and were born slightly earlier than the control groups; these variables were included as covariates in the statistical analysis. The main finding was that children exposed to antenatal glucocorticoid treatment had significantly increased cortisol reactivity to a standardized laboratory stressor, the Trier Social Stress Test for Children (TSST-C), compared with both control groups. Although these data are the most comprehensive to date, they are still cross-sectional and observational. Pr
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prenatal glucocorticoids and long-term programming
Seckl (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.151u049 · Cited by 825 · cited 6×
“In animal models, the developing HPA axis appears particularly vulnerable to excess glucocorticoids (4), yet the evidence for detrimental effects of antenatal glucocorticoids on human HPA axis activity has been less clear-cut.”
BackgroundInfluentialDalziel, S. R., Walker, N. K., Parag, V., Mantell, C., Rea, H. H., Rodgers, A., & Harding, J. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66617-2 · Cited by 461
A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum
Jung, C., Ho, J. T., Torpy, D. J., Rogers, A., Doogue, M., Lewis, J. G., Czajko, R. J., & Inder, W. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2395 · Cited by 394
Alexander, N., Rosenlöcher, F., Stalder, T., Linke, J., Distler, W., Morgner, J., & Kirschbaum, C. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1970 · Cited by 211
Davis, E. P., Waffarn, F., & Sandman, C. A. (2011) · Developmental Psychobiology · doi:10.1002/dev.20510 · Cited by 136
Cited by
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Räikkönen, K., Gissler, M., & Kajantie, E. (2020) · JAMA · doi:10.1001/jama.2020.3937 · Cited by 327
Braun, T., Challis, J. R., Newnham, J. P., & Sloboda, D. M. (2013) · Endocrine Reviews · doi:10.1210/er.2013-1012 · Cited by 196
Fetal endocrine therapy for congenital adrenal hyperplasia should not be done
Miller, W. L. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.01.005 · Cited by 40
Prenatal genetic testing and treatment for congenital adrenal hyperplasia
Simpson, J. L., & Rechitsky, S. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.11.041 · Cited by 36
Metadata
- Authors
- Reynolds, R. M., & Seckl, J. R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-10
- Volume
- 97
- Issue
- 10
- Pages
- 3457-3459
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2076724790
- Cited by
- 31
- References
- 6
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.